Literature DB >> 25633641

Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).

V Milovanov1, A Sardi2, P Ledakis3, N Aydin4, C Nieroda5, M Sittig6, M Nunez7, V Gushchin8.   

Abstract

BACKGROUND: The role of SC before CRS/HIPEC for patients with PMCA is unclear. This study explores the effect of SC prior to CRS/HIPEC on overall survival (OS) in patients with PMCA.
METHODS: 72 patients with recently diagnosed PMCA who underwent CRS/HIPEC were identified from a prospective database. Thirty patients had SC before CRS/HIPEC (Group 1) and 42 did not (Group 2). Patients who were referred to our center after multiple lines of SC were excluded from this analysis. OS was estimated.
RESULTS: Median follow-up was 3.2 years. Groups were similar regarding lymph node positivity, postoperative SC and rate of complete cytoreduction. Twenty-four (80%) patients in Group 1 and 21 (50%) in Group 2 had high grade histology (HG) (p = 0.01). OS from CRS/HIPEC at 1, 2, and 3 years was 93, 68, 51% in Group 1 and 82, 64, 60% in Group 2, respectively (p = 0.74). Among HG patients 3-year survival was 36% in the SC group vs. 35% in the group without SC (p = 0.67). The 3-year OS for patients with low grade (LG) tumors was 100% in the SC group vs. 79% in the group with no prior SC (p = 0.26). Among patients with signet ring cell (SRC) histology, 1, 2 and 3-year survival was 94, 67 and 22% in the SC group vs. 43, 14, 14% in the group with no SC, respectively (p = 0.028). There were only 6 patients with LG PMCA who received prior SC.
CONCLUSIONS: Preoperative SC could improve the prognosis of patients with high-grade PMCA with SRC histology.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Mucinous carcinomatosis of appendiceal origin; Systemic chemotherapy

Mesh:

Substances:

Year:  2015        PMID: 25633641     DOI: 10.1016/j.ejso.2015.01.005

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  11 in total

1.  Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative.

Authors:  Nick C Levinsky; Mackenzie C Morris; Koffi Wima; Jeffrey J Sussman; Syed A Ahmad; Jordan M Cloyd; Charles Kimbrough; Keith Fournier; Andrew Lee; Sean Dineen; Sophie Dessureault; Jula Veerapong; Joel M Baumgartner; Callisia Clarke; Mohammad Y Zaidi; Charles A Staley; Shishir K Maithel; Jennifer Leiting; Travis Grotz; Laura Lambert; Ryan J Hendrix; Sean Ronnekleiv-Kelly; Courtney Pokrzywa; Mustafa Raoof; Oliver S Eng; Fabian M Johnston; Jonathan Greer; Sameer H Patel
Journal:  J Gastrointest Surg       Date:  2019-08-19       Impact factor: 3.452

Review 2.  The Landmark Series: Appendiceal Primary Peritoneal Surface Malignancy.

Authors:  Alexandra Gangi; Rupen Shah
Journal:  Ann Surg Oncol       Date:  2021-12-01       Impact factor: 5.344

3.  Survival and prognostic factors for postoperative primary appendiceal cancer: a retrospective cohort study based on the Surveillance, Epidemiology, and End Results database.

Authors:  Ying Wang; Yiting Geng; Wenwei Hu
Journal:  J Gastrointest Oncol       Date:  2022-06

4.  Survival in Total Preoperative vs. Perioperative Chemotherapy for Patients with Metastatic High-Grade Appendiceal Adenocarcinoma Undergoing CRS/HIPEC.

Authors:  Ryan B Morgan; Allie Yan; Ankit Dhiman; Ardaman Shergill; Blase Polite; Kiran K Turaga; Oliver S Eng
Journal:  J Gastrointest Surg       Date:  2022-07-25       Impact factor: 3.267

Review 5.  Advances in the management of peritoneal malignancies.

Authors:  Vahan Kepenekian; Aditi Bhatt; Julien Péron; Mohammad Alyami; Nazim Benzerdjeb; Naoual Bakrin; Claire Falandry; Guillaume Passot; Pascal Rousset; Olivier Glehen
Journal:  Nat Rev Clin Oncol       Date:  2022-09-07       Impact factor: 65.011

Review 6.  Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives.

Authors:  J Spiliotis; E Halkia; E de Bree
Journal:  Curr Oncol       Date:  2016-06-09       Impact factor: 3.677

Review 7.  Consensuses and controversies on pseudomyxoma peritonei: a review of the published consensus statements and guidelines.

Authors:  Yu-Lin Lin; Da-Zhao Xu; Xin-Bao Li; Feng-Cai Yan; Hong-Bin Xu; Zheng Peng; Yan Li
Journal:  Orphanet J Rare Dis       Date:  2021-02-13       Impact factor: 4.123

8.  Diagnosis and Treatment of Mucinous Appendiceal Neoplasm Presented as Acute Appendicitis.

Authors:  Ioannis Kehagias; Apollon Zygomalas; Georgios Markopoulos; Thanasis Papandreou; Pantelis Kraniotis
Journal:  Case Rep Oncol Med       Date:  2016-03-14

9.  Impact of adjuvant chemotherapy on outcomes in appendiceal cancer.

Authors:  Bhaskar C Kolla; Ashley Petersen; Madhuri Chengappa; Tulasi Gummadi; Chitra Ganesan; Wolfgang B Gaertner; Anne Blaes
Journal:  Cancer Med       Date:  2020-03-19       Impact factor: 4.452

Review 10.  A case report of appendix mucinous adenocarcinoma that recurred after additional surgery and a brief literature review.

Authors:  Wei Chen; Jun-Wen Ye; Xiao-Ping Tan; Xiang Peng; Yan Zhang; Jing-Lin Liang; Mei-Jin Huang
Journal:  BMC Surg       Date:  2020-08-10       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.